Previous research in male and female rats selectively bred for high or low locomotor reactivity to novelty found that bred High Responders (bHRs) acquire cocaine self-administration more rapidly than bred Low Responders (bLRs) and that bHR females in particular self-administered more cocaine than the other groups.
Patel, D. M., Arnold, P. Y., White, G. A., Nardella, J. P. & Mannie, M. D. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
The clinical use of cetuximab in the treatment of HNSCC is significantly limited by the intrinsic resistance observed in most patients and by the onset of acquired resistance arising in responders, despite its proven efficacy.
Our study indicates that PBLs from sALS patients are strong responders to systemic signals or local signals acquired by cell trafficking, representing changes in gene expression similar to those present in brain and spinal cord of sALS patients.
Despite its efficacy, the clinical use of cetuximab is significantly limited by the intrinsic resistance observed in a number of patients and by the onset of acquired resistance often arising in responders.
Of equal importance, 20% of tumours display primary resistance to platinum compounds while the majority of initial responders will relapse, often as a result of acquired drug resistance [ 7, 8].
Since the acquired resistance signature is already highly represented in non-responders and that it seems unlikely that the numerous expression changes occurring on a global level would evolve in a relatively short period of time, our results appear to support the conventional, clonal selection model for tumor progression and acquired chemoresistance [1].
In a previous study, we reported the risk of developing clinical acquired immune deficiency syndrome (AIDS) or death is 2-fold higher in HBV vaccine non-responders compared to responders after adjusting for HIV disease-related factors such as CD4 count, viral load (VL), and use of combination antiretroviral therapy (cART) [ 10].
Approximately 25% of patients with HR+ disease have intrinsic endocrine resistance, while responders to initial endocrine therapy will ultimately have disease progression as a result of acquired resistance.
Unfortunately, some patients are constitutively resistant to lapatinib treatment, and, even in responders, the disease often progresses because of the selection of tumor cells that have acquired resistance to the drug.
